AU Patent

AU2006313701B2 — Novel pyridopyrazines and their use as modulators of kinases

Assigned to Aeterna Zentaris GmbH · Expires 2012-05-31 · 14y expired

What this patent protects

The invention relates to novel pyrido[2,3-b]pyrazine derivatives of the general formulae (I) and (II), their preparation and use as medicaments, in particular for the treatment of malignant and other disorders involving pathological cell proliferations.

USPTO Abstract

The invention relates to novel pyrido[2,3-b]pyrazine derivatives of the general formulae (I) and (II), their preparation and use as medicaments, in particular for the treatment of malignant and other disorders involving pathological cell proliferations.

Drugs covered by this patent

Patent Metadata

Patent number
AU2006313701B2
Jurisdiction
AU
Classification
—
Expires
2012-05-31
Drug substance claim
No
Drug product claim
No
Assignee
Aeterna Zentaris GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.